{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:24:07Z","timestamp":1787387047940,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"BeOne Medicines Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12325-026-03661-w","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T08:20:42Z","timestamp":1781166042000},"page":"4042-4059","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-6562","authenticated-orcid":false,"given":"Mazyar","family":"Shadman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2901-0769","authenticated-orcid":false,"given":"Talha","family":"Munir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Mohseninejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Guthrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Lefebure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhys","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-5017","authenticated-orcid":false,"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"3661_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-0881-4","volume":"22","author":"A Scheffold","year":"2020","unstructured":"Scheffold A, Stilgenbauer S. Revolution of chronic lymphocytic leukemia therapy: the chemo-free treatment paradigm. Curr Oncol Rep. 2020;22:16.","journal-title":"Curr Oncol Rep"},{"key":"3661_CR2","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1182\/blood-2012-02-362624","volume":"120","author":"JA Woyach","year":"2012","unstructured":"Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012;120:1175\u201384.","journal-title":"Blood"},{"key":"3661_CR3","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","volume":"6","author":"PM Barr","year":"2022","unstructured":"Barr PM, Owen C, Robak T, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6:3440\u201350.","journal-title":"Blood Adv."},{"key":"3661_CR4","doi-asserted-by":"publisher","first-page":"1624761","DOI":"10.3389\/fonc.2025.1624761","volume":"15","author":"J Ivanovic","year":"2025","unstructured":"Ivanovic J, Otasevic V, Markovic K, et al. Real-world cardiovascular risks of ibrutinib in chronic lymphocytic leukemia: a retrospective study. Front Oncol. 2025;15:1624761.","journal-title":"Front Oncol."},{"key":"3661_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/jha2.638","volume":"4","author":"A Mato","year":"2023","unstructured":"Mato A, Tang B, Azmi S, et al. A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States. EJHaem. 2023;4:135\u201344.","journal-title":"EJHaem."},{"key":"3661_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40256-025-00757-6","volume":"26","author":"L Spadafora","year":"2026","unstructured":"Spadafora L, Russo F, Bukowska-Olech E, et al. Cardiovascular safety of bruton tyrosine kinase inhibitors: from ibrutinib to next-generation agents. Am J Cardiovasc Drugs. 2026;26:21\u201334.","journal-title":"Am J Cardiovasc Drugs."},{"key":"3661_CR7","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1182\/blood.2024024476","volume":"146","author":"JP Sharman","year":"2025","unstructured":"Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN. Blood. 2025;146:1276\u201385.","journal-title":"Blood."},{"key":"3661_CR8","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1021\/acs.jmedchem.2c01938","volume":"66","author":"Y Guo","year":"2023","unstructured":"Guo Y, Hu N, Liu Y, et al. Discovery of BGB-8035, a highly selective covalent inhibitor of Bruton\u2019s tyrosine kinase for B-cell malignancies and autoimmune diseases. J Med Chem. 2023;66:4025\u201344.","journal-title":"J Med Chem."},{"key":"3661_CR9","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1080\/17512433.2021.1978288","volume":"14","author":"CS Tam","year":"2021","unstructured":"Tam CS, Ou YC, Trotman J, Opat S. Clinical pharmacology and PK\/PD translation of the second-generation Bruton\u2019s tyrosine kinase inhibitor, zanubrutinib. Expert Rev Clin Pharmacol. 2021;14:1329\u201344.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"3661_CR10","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1182\/blood-2025-2129","volume":"146","author":"C Tam","year":"2025","unstructured":"Tam C, Munir T, Robak T, et al. Sustained efficacy of zanubrutinib (zanu) vs bendamustine+ rituximab (BR) in treatment (tx)-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma (TN SLL\/CLL) and continued favorable survival in non-randomized patients (pts) with del (17p): 6-year follow-up in the phase 3 SEQUOIA study. Blood. 2025;146:2129.","journal-title":"Blood."},{"key":"3661_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.clml.2024.05.019","volume":"25","author":"A Alsouqi","year":"2025","unstructured":"Alsouqi A, Woyach JA. SOHO state of the art updates and next questions | covalent Bruton\u2019s tyrosine kinase inhibitors in chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2025;25:89\u201395.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3661_CR12","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.hoc.2025.05.006","volume":"39","author":"SA Bhat","year":"2025","unstructured":"Bhat SA, Woyach JA. Frontline treatment of chronic lymphocytic leukemia with continuous Bruton\u2019s tyrosine kinase inhibitors: a comprehensive overview. Hematol Oncol Clin North Am. 2025;39:875\u201384.","journal-title":"Hematol Oncol Clin North Am"},{"key":"3661_CR13","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1182\/blood.2024024667","volume":"144","author":"JR Brown","year":"2024","unstructured":"Brown JR, Eichhorst B, Lamanna N, et al. Sustained benefit of zanubrutinib vs ibrutinib in patients with R\/R CLL\/SLL: final comparative analysis of ALPINE. Blood. 2024;144:2706\u201317.","journal-title":"Blood"},{"key":"3661_CR14","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.21.01210","volume":"39","author":"JC Byrd","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39:3441\u201352.","journal-title":"J Clin Oncol."},{"key":"3661_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10223-0","volume":"22","author":"ZA Mkhwanazi","year":"2022","unstructured":"Mkhwanazi ZA, Nyambuya TM, Mfusi SA, Nkambule BB. Prognostic markers in patients with chronic lymphocytic leukaemia on targeted therapy, chemoimmunotherapy with anti-CD20 monoclonal antibody: a systematic review and meta-analysis of prognostic factors. BMC Cancer. 2022;22:1218.","journal-title":"BMC Cancer"},{"key":"3661_CR16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989X17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, et al. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38:200\u201311.","journal-title":"Med Decis Making."},{"key":"3661_CR17","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1200\/JCO-24-02265","volume":"43","author":"M Shadman","year":"2025","unstructured":"Shadman M, Munir T, Robak T, et al. Zanubrutinib versus bendamustine and rituximab in patients with treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma: median 5-year follow-up of SEQUOIA. J Clin Oncol. 2025;43:780\u20137.","journal-title":"J Clin Oncol."},{"key":"3661_CR18","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683\u201391.","journal-title":"J Clin Epidemiol"},{"key":"3661_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1017\/S0266462319000333","volume":"35","author":"DM Phillippo","year":"2019","unstructured":"Phillippo DM, Dias S, Elsada A, Ades AE, Welton NJ. Population adjustment methods for indirect comparisons: a review of National Institute for Health and Care Excellence technology appraisals. Int J Technol Assess Health Care. 2019;35:221\u20138.","journal-title":"Int J Technol Assess Health Care"},{"key":"3661_CR20","volume-title":"NICE DSU technical support document 18: Methods for population-adjusted indirect comparisons in submission to NICE","author":"DM Phillippo","year":"2016","unstructured":"Phillippo DM, Ades AE, Dias S, et al. NICE DSU technical support document 18: Methods for population-adjusted indirect comparisons in submission to NICE. NICE; 2016."},{"key":"3661_CR21","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025018536","author":"M Shadman","year":"2026","unstructured":"Shadman M, Tam CS, Brander DM, et al. An indirect comparison of Zanubrutinib vs Acalabrutinib plus Venetoclax in patients with treatment-naive CLL. Blood Adv. 2026. https:\/\/doi.org\/10.1182\/bloodadvances.2025018536.","journal-title":"Blood Adv"},{"key":"3661_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"key":"3661_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.70010","author":"RK Wood","year":"2025","unstructured":"Wood RK, Elsharawi I, Goudie M, et al. The ABCs of IGHV testing in chronic lymphocytic leukaemia: current recommendations, ongoing challenges, and future directions. Int J Lab Hematol. 2025. https:\/\/doi.org\/10.1111\/ijlh.70010.","journal-title":"Int J Lab Hematol"},{"key":"3661_CR24","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jval.2024.05.015","volume":"27","author":"S Tanaka","year":"2024","unstructured":"Tanaka S, Igarashi A, De Moor R, et al. A targeted review of worldwide indirect treatment comparison guidelines and best practices. Value Health. 2024;27:1179\u201390.","journal-title":"Value Health"},{"key":"3661_CR25","doi-asserted-by":"publisher","first-page":"471","DOI":"10.21873\/anticanres.16835","volume":"44","author":"G Beis","year":"2024","unstructured":"Beis G, Iliopoulos A, Papasotiriou I. An overview of introductory and advanced survival analysis methods in clinical applications: where have we come so far? Anticancer Res. 2024;44:471\u201387.","journal-title":"Anticancer Res"},{"key":"3661_CR26","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jamaoncol.2018.0518","volume":"4","author":"M Horiguchi","year":"2018","unstructured":"Horiguchi M, Tian L, Uno H, et al. Quantification of long-term survival benefit in a comparative oncology clinical study. JAMA Oncol. 2018;4:881\u20132.","journal-title":"JAMA Oncol."},{"key":"3661_CR27","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.3324\/haematol.2013.100784","volume":"99","author":"J Delgado","year":"2014","unstructured":"Delgado J, Pereira A, Villamor N, Lopez-Guillermo A, Rozman C. Survival analysis in hematologic malignancies: recommendations for clinicians. Haematologica. 2014;99:1410\u201320.","journal-title":"Haematologica"},{"key":"3661_CR28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood.2020005877","volume":"136","author":"PA Thompson","year":"2020","unstructured":"Thompson PA. Occupy BTK: the key to controlling CLL. Blood. 2020;136:4\u20136.","journal-title":"Blood"},{"key":"3661_CR29","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1182\/blood.2019003715","volume":"136","author":"C Sun","year":"2020","unstructured":"Sun C, Nierman P, Kendall EK, et al. Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib. Blood. 2020;136:93\u2013105.","journal-title":"Blood"},{"key":"3661_CR30","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1182\/bloodadvances.2023012142","volume":"8","author":"AS Kittai","year":"2024","unstructured":"Kittai AS, Allan JN, James D, et al. An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL. Blood Adv. 2024;8:2861\u20139.","journal-title":"Blood Adv"},{"key":"3661_CR31","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.3390\/ph18111674","volume":"18","author":"Y Alatawi","year":"2025","unstructured":"Alatawi Y, Alanazi FE, Alattar A, et al. Therapeutic impact of zanubrutinib in chronic lymphocytic leukemia: evidence from a systematic review and single-arm meta-analysis. Pharmaceuticals (Basel). 2025;18:1674.","journal-title":"Pharmaceuticals (Basel)."},{"key":"3661_CR32","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1007\/s00277-023-05486-x","volume":"103","author":"S Yin","year":"2024","unstructured":"Yin S, Zheng X, Zhang W, et al. Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia\/small lymphocytic lymphoma: a systematic review and meta-analysis. Ann Hematol. 2024;103:2231\u201344.","journal-title":"Ann Hematol."},{"key":"3661_CR33","doi-asserted-by":"crossref","unstructured":"Zinzani PL, Williams R, Xue M, et al. A meta-analysis investigating response rates with continuous bruton tyrosine kinase inhibitor monotherapies in the treatment of B cell lymphomas. Oncol Ther. 2026.","DOI":"10.1007\/s40487-026-00425-y"},{"key":"3661_CR34","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/cancers17010119","volume":"17","author":"S Molica","year":"2025","unstructured":"Molica S, Allsup D. Chronic lymphocytic leukemia care and beyond: navigating the needs of long-term survivors. Cancers (Basel). 2025;17:119.","journal-title":"Cancers (Basel)"},{"key":"3661_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.74","volume":"8","author":"P Ghia","year":"2024","unstructured":"Ghia P, Owen C, Allan JN, et al. First-line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age-matched general population: a pooled post hoc analysis. Hemasphere. 2024;8:e74.","journal-title":"Hemasphere"},{"key":"3661_CR36","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3324\/haematol.2013.101378","volume":"99","author":"D Catovsky","year":"2014","unstructured":"Catovsky D, Wade R, Else M. The clinical significance of patients\u2019 sex in chronic lymphocytic leukemia. Haematologica. 2014;99:1088\u201394.","journal-title":"Haematologica"},{"key":"3661_CR37","doi-asserted-by":"publisher","DOI":"10.1177\/11795549241275665","volume":"18","author":"M Narang","year":"2024","unstructured":"Narang M, Horn C, Lee E. Clinician perspective on once-daily Zanubrutinib dosing for B-cell malignancies at a single center. Clin Med Insights Oncol. 2024;18:11795549241275665.","journal-title":"Clin Med Insights Oncol"},{"key":"3661_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01434-2","volume":"16","author":"MS Davids","year":"2026","unstructured":"Davids MS, Stilgenbauer S, Tam CS. First-line treatment for CLL in the era of targeted therapy. Blood Cancer J. 2026;16:19.","journal-title":"Blood Cancer J"},{"key":"3661_CR39","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1080\/17474086.2023.2271170","volume":"16","author":"S Molica","year":"2023","unstructured":"Molica S. Redefining efficacy and safety endpoints for chronic lymphocytic leukemia in the era of targeted therapy. Expert Rev Hematol. 2023;16:803\u20136.","journal-title":"Expert Rev Hematol"},{"key":"3661_CR40","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/17474086.2024.2366534","volume":"17","author":"S Molica","year":"2024","unstructured":"Molica S. Defining treatment success in chronic lymphocytic leukemia: exploring surrogate markers, comorbidities, and patient-centered endpoints. Expert Rev Hematol. 2024;17:279\u201385.","journal-title":"Expert Rev Hematol"},{"key":"3661_CR41","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13195-015-0109-2","volume":"7","author":"A Atri","year":"2015","unstructured":"Atri A, Hendrix SB, Pejovic V, et al. Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer\u2019s dementia: a pooled area under the curve analysis. Alzheimers Res Ther. 2015;7:28.","journal-title":"Alzheimers Res Ther."},{"key":"3661_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2025.101088","volume":"47","author":"CM Farinasso","year":"2025","unstructured":"Farinasso CM, Ferreira VL, Medeiros FC, et al. Matching-adjusted indirect comparison studies in oncology: a scoping review focused on reporting quality. Value Health. 2025;47:101088.","journal-title":"Value Health."},{"key":"3661_CR43","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","volume":"14","author":"JP Jansen","year":"2011","unstructured":"Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1. Value Health. 2011;14:417\u201328.","journal-title":"Value Health"},{"key":"3661_CR44","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/bcp.12150","volume":"77","author":"H Kim","year":"2014","unstructured":"Kim H, Gurrin L, Ademi Z, Liew D. Overview of methods for comparing the efficacies of drugs in the absence of head-to-head clinical trial data. Br J Clin Pharmacol. 2014;77:116\u201321.","journal-title":"Br J Clin Pharmacol"},{"key":"3661_CR45","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024537","volume":"9","author":"R Phillips","year":"2019","unstructured":"Phillips R, Hazell L, Sauzet O, Cornelius V. Analysis and reporting of adverse events in randomised controlled trials: a review. BMJ Open. 2019;9:e024537.","journal-title":"BMJ Open"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03661-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03661-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03661-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:04:28Z","timestamp":1787385868000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03661-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3661"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03661-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mazyar Shadman: Consulting, advisory boards, steering committees, or data safety monitoring committees: AbbVie, Ascentage, Genentech, AstraZeneca, Genmab, Janssen, BeOne Medicines, Ltd, BMS, MorphoSys\/Incyte, Kite Pharma, Lilly, Fate Therapeutics, Nurix, Merck, Pfizer, Pierre Fabre; Research funding: Genentech, BeOne Medicines, Ltd, AstraZeneca, Genmab, MorphoSys\/Incyte, Sana Biotechnology, Nurix, Merck, Janssen; Employment (spouse): BMS; Stock options: Koi Biotherapeutics. Talha Munir: Honoraria: BeOne Medicines, Ltd, AstraZeneca, Sobi, Roche, Janssen, AbbVie, Lilly; Consulting: AbbVie, BeOne Medicines, Ltd, Sobi, Alexion, Novartis, Janssen, AstraZeneca, Lilly, Roche; Research grants: Janssen, AbbVie; Travel, accommodations, or expenses: Alexion, BeOne Medicines, Ltd, AbbVie, Janssen, AstraZeneca; Advisory board: AbbVie, BeOne Medicines, Ltd, AstraZeneca, Janssen. Sheng Xu, Keri Yang, Leyla Mohseninejad, Grace Guthrie, Rhys Williams: Employment and may own stock: BeOne Medicines, Ltd. Jamie Hirata: Employment: BeOne Medicines, Ltd (currently), Genentech; Stocks or other ownership: BeOne Medicines, Ltd, Roche. Marcus Lefebure: Employment: BeOne Medicines, Ltd (Feb 2025 onwards), Roche (until 2025); Stock or other ownership: BeOne Medicines, Ltd; Roche. Constantine S. Tam: Honoraria: BeOne Medicines, Ltd, Janssen, AbbVie, AstraZeneca, Gilead, Lilly, Merck; Research funding: BeOne Medicines, Ltd, Janssen, AbbVie.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics committee approval was not required for these post hoc analyses. The SEQUOIA, RESONATE-2, and ELEVATE-TN trials were approved by the applicable ethics committees and followed the ethical principles of Good Clinical Practice, International Conference on Harmonization guidelines, and the Declaration of Helsinki. Patients provided written informed consent to participate in each study","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}